Niacin extended-release/ lovastatin: combination therapy for lipid disorders

References

• AMERICAN HEART ASSOCIATION: 2002 Heart and Stroke Statistical Update. American Heart Association, Dallas, TX, USA (2001).
   Google Scholar
• WONG ND, KASHYAP M: Cholesterol and lipids. In: Preventive Cardiology Wong ND, Black HR & Gardin JM (Eds), McGraw-Hill, New York, USA (2000):165–193.
   Google Scholar
• GOTTO AM: Triglyceride as a risk factor for coronary artery disease. Am. J. Cardiol (1998) 82(9A):22Q–25Q.
   Google Scholar
• COMMITTEE ON PRINCIPAL INVESTIGATION: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart j (1978) 40:1069–1118.
   PubMedGoogle Scholar
• LIPID RESEARCH CLINICS PROGRAM: The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA (1984) 251:351–364.
   Google Scholar
• FRICK MH, ELO 0, KAPPA K et al: HELSINKI Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl. Med. (1987) 317:1237–1245.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA (1998) 279:1615–1622.
   PubMed Web of Science ®Google Scholar
• Clofibrate and niacin in coronary heart disease. JAMA (1975) 231:360–381.
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• BLOOMFIELD-RUBINS H, ROBINS SJ, COLLINS D et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl. Med. (1999) 341:410–418.
   PubMedGoogle Scholar
• ROBINS SJ, COLLLINS D, WITTES JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA (2001) 285(12):1585–1591.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• •Showed benefit of statin therapy for diabetics as well as those with LDL cholesterol 100 mg/d1.
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• ••The most recent guidelines formanagement of dyslipidaemia.
   Google Scholar
• TAHER TH, DZAVIK V, RETEFF EM et al.: Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am. Cardiol (2002) 89:390–394.
   PubMed Web of Science ®Google Scholar
• BROWN BG, BARDSLEY J, POULIN D et al.: Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol 100mg/dlin patients with hyperlipidemia and coronary artery disease. Am.' Cardiol (1997) 80:111–115.
   PubMed Web of Science ®Google Scholar
• VAN JT, PAN J,WASTY T et al: Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am. J. Cardiol (2002) 89:1306–1308.
   PubMed Web of Science ®Google Scholar
• MCKENNEY JM, MCCORMICK LS, SCHAEFER EJ et al.: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am.j Cardiol (2001) 88:270–274.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI G, CASSINOTTI M, VECCHIO G et al.: Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler. Thromb. (1994) 14:1569–1575.
   PubMedGoogle Scholar
• YUAN J, TSAI MY, HUNNINGHAKE DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis (1994) 110:1–11.
   PubMed Web of Science ®Google Scholar
• KNOPP RH, ALAGONA P, DAVIDSON M et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism (1998) 47(9):1097–1104.
   PubMed Web of Science ®Google Scholar
• TAVINTHARAN S, KASHYAP ML: The benefits of niacin in atherosclerosis. Current Atherosclerosis Reports (2001) 3:74–82.
   PubMedGoogle Scholar
• •Review of niacin.
   Google Scholar
• KNOPP RH: Evaluating niacin in its various forms. Am. J. Cardiol (2000) 86(Suppl. 12A):51L–56L.
   Google Scholar
• MCKENNY JM, PROCTOR JD, HARRIS S, CHINCHILI VM: A comparison of the efficacy and toxic effects of sustained- versus immediate-release
   Google Scholar
• •• niacin in hypercholesterolemic patients. JA/VIA (1994) 271:672–677.
   Google Scholar
• KNOPP RH, GINSBERG J, ALBERS JJ et al.: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues of mechanism of action of niacin. Metabolism (1985) 34(7):642–650.
   PubMed Web of Science ®Google Scholar
• PIEPHO RW: The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol (2000) 86:35L–40L.
   Google Scholar
• STERN RH, FREEMAN D, SPENCE JD: Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action. Metabolism (1992) 41:879–881.
   PubMedGoogle Scholar
• MORGAN JM, CAPUZZI DM, GUYTON JR: A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. Am. .1. Cardiol (1998) 82:29U–34U.
   Google Scholar
• CAPUZZI DM, GUYTON JR, MORGAN JM et al.: Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Jim. .1 Cardiol (1998) 82:74U–81U.
   Google Scholar
• HENWOOD JM, HEEL R: Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs (1988) 36:429–454.
   Google Scholar
• TOBERT JT: Efficacy and long-term adverse effect pattern of lovastatin. Am. Cardiol (1988) 62:28J–34J.
   Google Scholar
• KNOPP RH: Drug therapy: drug treatment of lipid disorders. N Engl. .1. Med. (1999) 341(7):498–511.
   Google Scholar
• ZocorTm prescribing information. Merck & Co., Inc., Whitehouse Station, NJ, USA (May 2002).
   Google Scholar
• BAKKER-ARKEMA RG, DAVIDSON MH, GOLDSTEIN RJ et al: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA (1996) 275(2):128–133.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, DAVENPORT J, BABIKIAN V et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation (2001) 103(23):2828–2833.
   PubMedGoogle Scholar
• BROWN BG, ZHAO X-Q, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl. .1. Med. (2001) 345:1583–1592.
   Google Scholar
• •Outcome data with combination therapy.
   Google Scholar
• Lovastatin. In: The Merck Index. An Encyclopedia of Chemicals, Drugs, and Biologicals. Budavari S, O'Neil MJ, Smith A, Heckelman PE (Eds). Merck & Co., Inc. NJ, USA (1989):878–879.
   Google Scholar
• Niacin. In: The Merck Index. An Encyclopedia of Chemicals, Drugs, and Biologicals. Budavari S, O'Neil MJ, Smith A, Heckelman PE (Eds). Merck & Co., Inc. NJ, USA (1989):1030–1031.
   Google Scholar
• GUYTON JR, GOLDBERG AC, KREISBERG RA et al.: Effectiveness of once-daily dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am. J. Cardiol (1998) 82(6):737–743.
   PubMedGoogle Scholar
• KASHYAP ML, MCGOVERN ME, BERRA K et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol (2002) 89:672–678.
   PubMed Web of Science ®Google Scholar
• ••Long-term safety and efficacy trial ofniacin ER/lovastatin.
   Google Scholar
• SAKAI T, KAMANNA VS, KASHYAP ML: Niacin but not gemfibrozil increases Lp-AI, a cardioprotective subfraction of HDL, in patients with low HDL-cholesterol. Arteriosc/er. DIF017711. V3SC. (2001) 21:1783–1789.
   PubMed Web of Science ®Google Scholar
• •New data on the effect of niacin on HDL subfractions.
   Google Scholar
• JIN FY, KAMANNA VS, KASHYAP ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arteciosder. DIF017711. V3SC. Biol. (1997) 17:2020–2028.
   Google Scholar
• •Describes a novel mechanism of action of niacin on raising HDL.
   Google Scholar
• CARLSON LA: Studies on the effect of nicotinic acid on catecholamide stimulated lipolysis in adipose tissue M vitro. Acta Med Scand. (1963) 173:719–722.
   PubMed Web of Science ®Google Scholar
• JIN FY, KAMANNA VS, KASHYAP ML: Niacin accelerates intracellular apoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arteciosder. Thr017711. V3SC. (1999) 19:1051–1059.
   PubMed Web of Science ®Google Scholar
• •Describes a novel mechanism of action of niacin on decreasing atherogenic apoB containing lipoproteins.
   Google Scholar
• GANJI SH, TAVINTHARAN S, ZHU D, KAMANNA VS, KASHYAP ML: Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis [abstract]. Arteciosder. Thrornb. Vasc. Biol. (2002) 22:878A.
   Google Scholar
• •New data on one target of niacin effect on triglycerides.
   Google Scholar
• KAMANNA VS, KASHAYP ML: Mechanism of action of niacin on lipoprotein metabolism. Curc Artheroscler. Rep. (2000) 2:36–46.
   PubMedGoogle Scholar
• KASHYAP ML: Mechanistic studies of highdensity lipoproteins. Am. J. Cardiol (1998) 82:42U–48U.
   Google Scholar
• SUPERKO HR, KRAUSS RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis (1992) 95(1):69–76.
   PubMed Web of Science ®Google Scholar
• SUPERKO HR: What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials. Curc Opin. Lipidol (1996) 7:363–368.
   PubMedGoogle Scholar
• GUYTON JR, BLAZING BA, HAGAR J et al.: for Niaspan-Gemfibrozil Study Group: Extended release niacin versus gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch. Intern. Med. (2000) 160:1177–1184.
   PubMedGoogle Scholar
• GARG R, MALINOW M, PETTINGER M, UPSON B, HUNNINGHAKE D: Niacin treatment increase plasma homocyst(e)ine levels. Am. Heart (1999) 138(6 Pt. 1):1082–1087.
   Google Scholar
• MAGONI AA, JACKSON SH: Homocysteine and cardiovascular disease: Current perspective and future prospects. Am. J. Med. (2002) 112(7):556–565.
   PubMed Web of Science ®Google Scholar
• MevacorTm prescribing information. Merck & Co., Inc. Whitehouse Station, NJ, USA (2000).
   Google Scholar
• MARTIN G, DUEZ H, BLANQUART C et al.: Statin-induced inhibition of the Rho-signaling pathway activates PPARcc and induces HDLGin. Invest. (2001)107(11):1423–1432.
   Google Scholar
• •New data on the action of cerivastatin on apoA-I.
   Google Scholar
• SCHAEFER JR, SCHWEER H, IKEWAKI K et al.: Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis (1999) 144(1):177–184.
   PubMedGoogle Scholar
• ALBERTS AW: Discovery, biochemistry, and biology of lovastatin. Am. J. Cardiol (1998) 62:10J–15J.
   Google Scholar
• BEIGEL Y, FUCHS J, SNIR M, GREEN P,
   Google Scholar
• •• LURIE Y, DJALDETTI M: Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheaologic parameters, platelet activity, and red blood cell morphology. J. Clin. Pharmacol (1991) 31:512–517.
   Google Scholar
• TSUDA Y, SATOH K, KITADAI M, TAKAHASHI T, IZUMI Y, HOSOMI N: Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis (1996) 122:225–233.
   PubMed Web of Science ®Google Scholar
• CRISBY M, NORDIN-FREDRIKSSONG, SHAH PK, YANO J, ZHU J, NILSSON J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation (2001) 103:926–933.
   PubMedGoogle Scholar
• LAUFS U, MARRA D, NODE K, LIAO JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip 1). J. Bia Chem. (1999) 274:21926–21931.
   PubMed Web of Science ®Google Scholar
• YANG Z, KOZAI T, VAN DER LOO B, VISWAMBHARAN H et al: HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll. Cardiol (2000) 36:1691–1697.
   PubMed Web of Science ®Google Scholar
• MCFARLANE SI, MUNIYAPPA R, FRANCISCO R et al.: Pleiotropic effects of statins: lipid reduction and beyond. I Clin. Endocrinol Metab. (2002) 87(4):1451–1458.
   PubMed Web of Science ®Google Scholar
• MUSIAL J, UNDAS A, GAJEWSKI P, JANKOWSKI M, SYDOR W, SZCZEKLIK A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. j Cardiol (2001) 77:247–253.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA,SACKS F, BRAUNWALD E: Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 100:230–235.
   PubMed Web of Science ®Google Scholar
• AdvicorTm prescribing information. Kos Pharmaceuticals. Miami, FL, (2001).
   Google Scholar
• BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232:34–47.
   PubMed Web of Science ®Google Scholar
• KANTOLA T, KIVISTO KT, NEUVONEN PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol Titer. (1998) 63(4):397–402.
   PubMed Web of Science ®Google Scholar
• GUPTA EK, ITO MK: Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. (2002) 4:124–137.
   PubMedGoogle Scholar
• CANNER PL, BERGE KG, WENGER NK et al: Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. j. Am. Coll. Cardiol (1986) 8:1245–1255.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, NESSIM SA, JOHNSON RL, SANMARCO ME, AZEN SP, CASHIN-HEMPHILL L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 257:3233–3240.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ALBERS JJ, FISHER LD:Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl. I Med. (1990) 323:1289–1298.
   PubMed Web of Science ®Google Scholar
• WATERS D, HIGGINSON L, GLADSTONE P et al.: Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 89:959–968.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, AZEN SP, KRAMSCH DM et al.: The Monitored Atherosclerosis Regression Study (MARS): coronary angiographic changes with lovastatin therapy. Ann. Intern. Med. (1993) 119:969–976.
   PubMed Web of Science ®Google Scholar
• FURBERG CD, ADAMS HP, APPLEGATE WB et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 90:1679–1687.
   PubMed Web of Science ®Google Scholar
• BAYS HE, MCGOVERN ME, SIMMONS PD: Lipoprotein effects of a new dual component drug (extended-release niacin/lovastatin) compared to starting doses of atorvastatin and simvastatin. J. Amer. Coll. Card. (2002) 39(5, Suppl. A):245A (833–835; Abstract). Direct comparison of niacin ER/lovastatin combination therapy with atorvastatin and simvastatin.
   Google Scholar
• MOLNAR G, BERGE K, ROSE VEAR J et al.: The effect of nicotinic acid in diabetes mellitus. Metabolism (1964) 13:181–190.
   Google Scholar
• KAHN SE, BEARD JC, SCHWARTZ MW et al.: Increased I3-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes (1989) 38:562–568.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, VEGA GL, MCGOVERN ME et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated withType 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. (2002) 162(14):1568–1576.
   PubMedGoogle Scholar
• ••Safe use of niacin ER in diabetics.
   Google Scholar
• ELAM MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA (2000) 284:1263–1270.
   PubMed Web of Science ®Google Scholar
• •Safe use of niacin in diabetics.
   Google Scholar
• KNOPP RH: Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am. j Cardiol (1998) 82:24U–28U.
   Google Scholar